Wedbush Reiterated an Outperform on Cerulean Pharma (CERU) Following 3Q
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/21/2026
- Wall St rises in broad rebound; yields push markets towards weekly declines
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Wall Street sinks as bond yields rise, Walmart results disappoint
- Supermicro probe finds no senior management link to export violations
- Wolfe remains "broadly bullish on AI semis stocks", names Top Pick
- Hertz Global amends voting agreement with CK Amarillo after lawsuit
- SpaceX shares fall as second lockup period ends
Cerulean Pharma (CERU) Tops Q3 EPS by 2c
November 16, 2015 4:38 PM ESTCerulean Pharma (NASDAQ: CERU) reported Q3 EPS of ($0.39), $0.02 better than the analyst estimate of ($0.41).
For earnings history and earnings-related data on Cerulean Pharma (CERU) click here.
... MoreTrading Radar for 11/16: Agilent (A), Dillard's (DDS), YOU On Demand (YOD), Noah Holdings (NOAH) Report
November 13, 2015 3:09 PM ESTThe Trading Radar highlights key earnings and economic announcements for the next trading session:
Before Markets Open:
Economics:
8:30am EST
Earnings:
American Electric Technologies (Nasdaq: AETI) - consensus EPS $0.07
Argos Therapeutics (Nasdaq: ARGS) - consensus loss $0.92
Asure Software (Nasdaq: ASUR) - consensus EPS $0.08
BioLineRx (Nasdaq:... More
